Clinical trials
Uveal Melanoma clinical trials
Below are recruiting uveal melanoma clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05607095RecruitingPhase 1
TIL therapy for advanced uveal melanoma and sarcomas
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
Harrison, New YorkAges 18 years+ - NCT05502900RecruitingPhase 3
Melatonin after eye melanoma to lower spread risk
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
Stockholm, Stockholm CountyAges 18 years+ - NCT05733728Recruiting
Uveal melanoma medical record study
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
ViennaAges 18–99 - NCT06070012RecruitingPhase 2
Tebentafusp for untreated metastatic uveal melanoma
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Aurora, ColoradoAges 18 years+ - NCT06550674Recruiting
Genetic study for uveal melanoma risk
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
Clermont-Ferrand, Puy-de-DômeAges 18 years+ - NCT06627244RecruitingPhase 2
Study of tebentafusp and radioembolization for uveal melanoma that spread to the liver
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
Miami, FloridaAges 18 years+ - NCT06932757RecruitingPhase 2
Quisinostat after treatment for high-risk uveal melanoma
This trial tests whether taking quisinostat pills after standard treatment can lower the chance of uveal melanoma coming back in people whose original tumor had high-risk features. It is for patients who have finished their eye treatment (surgery or radiation) within the past 6 months and have no signs that the cancer has spread.
Miami, FloridaAges 19 years+ - NCT07015190RecruitingPhase 3
Darovasertib before surgery for eye melanoma
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT07057596RecruitingPhase 2
Tebentafusp before surgery for uveal melanoma in the liver
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
Berlin, State of BerlinAges 18 years+ - NCT07063875RecruitingPhase 1/Phase 2
Adding IL-2 to tebentafusp for advanced eye cancer
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
Sydney, New South WalesAges 18 years+ - NCT07136181RecruitingPhase 1/Phase 2
Study of NBM-BMX for advanced uveal melanoma that has spread
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Scottsdale, ArizonaAges 18 years+ - NCT01438658Recruiting
Test blood markers to help diagnose metastatic uveal melanoma
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
JerusalemAges Any age - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT07276386RecruitingPhase 2
Combination therapy for metastatic uveal melanoma
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Tampa, FloridaAges 18 years+ - NCT06519266RecruitingPhase 3
Liver treatment with immunotherapy for uveal melanoma that spread to the liver
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
GothenburgAges 18 years+ - NCT07076550RecruitingPhase 1
Radioactive drug for advanced melanoma
This trial tests a new radioactive drug (A9-3408) for people with advanced melanoma that has not responded to standard treatments. The drug is designed to target and destroy melanoma cells. The study is early phase, so it is mainly checking safety and how well the drug works.
Melbourne, VictoriaAges 18 years+ - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07627698RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Melanoma
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07421739Recruiting
Patient experience survey for choroidal melanoma trial
This study collects feedback from people already in the CoMpass trial for choroidal melanoma. You'll answer questions about your health and quality of life using a smartphone, laptop, or tablet.
East Melbourne, VictoriaAges Any age - NCT07203391RecruitingPhase 1
Tebentafusp and roginolisib for uveal melanoma
This trial tests a combination of two drugs, tebentafusp and roginolisib, for people with uveal melanoma that has spread or can't be removed. It aims to improve how long the immune system stays active against the cancer.
Sydney, New South WalesAges 18 years+ - NCT04424719Recruiting
Follow-up study for high-risk eye melanoma after treatment
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
ParisAges 18 years+ - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT07501117RecruitingPhase 1
Immunotherapy before eye removal for high-risk eye melanoma
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
Herlev, HerlevAges 18–80
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Uveal Melanoma trials by city
Studies with a site in or near these metro areas.
Uveal Melanoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for uveal melanoma?
- Yes. Clin2 currently lists 35 recruiting uveal melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a uveal melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a uveal melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.